Kelly Goldsmith, MD

Winship Cancer Institute of Emory University – Co-Leader of the Discovery and Developmental Therapeutics Research Program

Aflac Cancer and Blood Disorders Center – Director of the Neuroblastoma/MIBG Therapy Program

Emory University School of Medicine – Professor, Department of Pediatrics

Dr. Goldsmith specializes in the treatment of neuroblastoma, Wilms tumor, and other renal tumors of childhood. Her laboratory investigates the molecular mechanisms of chemotherapy resistance in pediatric neuroblastoma, focusing on experimental therapeutics that restore therapy sensitivity. Her translational research provided the concept behind a first in pediatrics Phase I trial of simvastatin in combination with chemotherapy for recurrent solid/CNS tumors of childhood. She is co-chair of a NANT Precision Medicine Study for recurrent neuroblastoma and chair of the AflacST1402 trial. Dr. Goldsmith rounds out her bench to bedside personality as the clinical director of the Refractory and Recurrent Neuroblastoma Program where she and her team work to match a relapsed patient with the appropriate therapy for their recurrent disease.

Dr. Goldsmith earned her MD from the University of Alabama School of Medicine in Birmingham, AL. She completed a residency in pediatrics and a fellowship in pediatric hematology and oncology at The Children’s Hospital of Philadelphia.